



**Oncode
Accelerator**

*Outsmarting cancer
Impacting lives*

Accelerating the Development of Cancer Therapies

Biologics

Advance Novel Antibodies From Concept to Clinic

The Biologics workstream of the Onco Accelerator program focuses on developing antibody-based immune therapies to harness the power of the immune system to tackle cancer. Keep reading to find out how you can tap into the potential of accelerated and de-risked biologics discovery and development.

Access State-of-the-Art Infrastructure Through Demonstrator Projects

Key to the success of the Onco Accelerator program is the selection and execution of high-quality Demonstrator Projects which aim to both validate the Onco Accelerator infrastructure while simultaneously addressing unmet medical needs. We invite international cancer researchers, from across academia and industry to apply for a Demonstrator Project and partner with us for preclinical development of promising assets.

Perform Antibody discovery

The unique cellular immunization method developed within the Antibody Therapy Group at University Medical Center Utrecht allows for generation of hundreds of unique antibody sequences, including against difficult targets. In combination with high-throughput in vitro functional characterization of candidates, this permits highly efficient early-stage antibody generation and lead discovery.

Find or Optimize your lead candidate

The Biologics Workstream offers broad coverage of most antibody modalities. The Workstream can perform *in vitro* characterization and lead optimization leveraging a combination of artificial intelligence-driven methodologies and *in vitro* selection on patient material and/or organoids.

Accelerate towards clinical validation

We offer the knowledge and tools necessary to ensure developability and to perform later development of promising assets, including Cell Line Generation and Process Development and Manufacturing of antibodies, through our preclinical and GMP-infrastructure specialized in early production of biologics. We can also provide regulatory guidance and undertake small scale antibody batch production under GMP conditions for first-in-human trials.

De-risk the development process

De-risk the preclinical pathway through the use of human tumor material in discovery and optimization stages, as well as in later toxicity and efficacy studies. Through the Biologics Workstream, you can also access the only and world-leading biomedical Accelerator Mass Spectrometry laboratory for microdosing studies to assess antibody characteristics in phase 0 trials.

Work With Us

Through Oncode Accelerator, we provide academic researchers, biotech drug developers and industry partners with access to expertise, facilities and technologies aimed at efficient, patient-centered development of cancer therapies up to early clinical validation. We are actively seeking ideas for Demonstrator Projects, through which you can access co-funding and support.

Reach out for more information

 demonstrators@oncodeaccelerator.nl

About Oncode Accelerator

Oncode Accelerator is a public-private partnership funded by the Dutch National Growth Fund (NGF), which aims to innovate and accelerate the preclinical development of new cancer therapies by placing cancer patients at the core. It is a collaboration between six coordinating partners:





**Get to
know us**

www.oncodeaccelerator.nl

 **Oncode Accelerator**